142例抗结核药物性肝损伤患者临床特征分析*

doi:10.3969/j.issn.1672-5069.2021.06.019

摘要/Abstract

摘要： 目的回顾抗结核药导致的药物性肝损伤(DILI)患者临床资料,旨在分析其临床特征、生化指标与临床结局。方法 2012年1月～2020年3月我院诊治的接受抗结核治疗期间被诊断为DILI患者142例,进行临床分型和肝损伤分度。结果在本组DILI患者中,诊断肝细胞型109例,胆汁淤积型17例,混合型16例;肝细胞型、胆汁淤积型和混合型患者血清ALT水平分别为(652.5±350.6)U/L、(172.6±92.8)U/L和(380.6±218.5)U/L,差异具有统计学意义(P<0.05),血清AST水平分别为(451.8±418.1)U/L、(185.5±105.2)U/L和(276.0±144.5)U/L,差异具有统计学意义(P<0.05),血清ALP水平分别为(94.5±77.5)U/L、(468.8±312.8)U/L和209.1±144.5)U/L,差异具有统计学意义(P<0.05),血清总胆红素分别为(42.3±32.3)μmol/L、(126.8±103.5)μmol/L和(57.8±42.8)μmol/L,差异具有统计学意义(P<0.05),血清白蛋白分别为(36.8±7.2)g/L、(32.2±6.8)g/L和(33.0±7.0)g/L,差异具有统计学意义(P<0.05);以肝损伤程度分组,本组轻度102例,中度14例,重度26例。轻度肝损伤患者以小于60岁、无基础肝病和以肝细胞型为主,与其他两组比,差异显著(P<0.05);本组临床治愈95例,未愈47例。治愈患者年龄偏轻、血清AST、ALP和总胆红素水平偏低、而血清白蛋白水平偏高,与未愈患者比,差异显著(P<0.05)。结论因抗结核药物导致的DILI患者以肝细胞损伤型居多,年龄大、存在低蛋白血症和高胆红素血症患者预后差,应予以特别的关注。

关键词: 药物性肝损伤, 抗结核药物, 临床分型, 肝损伤程度, 预后

Abstract: Objective The aim of this study was to summarize the clinical feature of patients with anti-tuberculosis drug-induced liver injury (DILI). Methods 142 patients with anti-tuberculosis DILI were enrolled in this study between January 2012 and March 2020, and the clinical catalogue and liver injury severity were clarified. Results There were hepatocyte injury in 109, cholestasis in 17 and mixed injury in 16 in our series; serum ALT levels in patients with hepatocyte injury, cholestasis and mixed injury were (652.5±350.6)U/L, (172.6±92.8)U/L and (380.6±218.5)U/L, significantly different among them (P<0.05), serum AST levels were (451.8±418.1)U/L, (185.5±105.2)U/L and (276.0±144.5)U/L, significantly different among them (P<0.05), serum ALP levels were (94.5±77.5)U/L, (468.8±312.8)U/L and 209.1±144.5)U/L(P<0.05), total serum bilirubin levels were (42.3±32.3)μmol/L, (126.8±103.5)μmol/L and (57.8±42.8)μmol/L(P<0.05) and serum albumin levels were (36.8±7.2)g/L, (32.2±6.8)g/L and (33.0±7.0)g/L, all significantly different among them (P<0.05); there were mild liver injury in 102, moderate liver injury in 14 and severe liver injury in 26 patients out of the 142 patients, and the clinical feature of patients with mild liver injury included more younger than 60 year old, no underlying liver disease and presented with hepatocy injury; 95 patients recovered and 47 not, and the recovered patients had more younger patients, low serum AST, ALP and bilirubin levels with relatively higher serum albumin levels, significantly different compared to those unrecovered (P<0.05). Conclusion The majority of patients with anti-tuberculosis DILI presents with hepatocyte injury, and those with low serum albumin and high total serum bilirubin levels are prone to have a poor prognosis.

Key words: Drug-induced liver injury, Anti-tuberculosis agents, Clinical catalogue, Liver injury severity, Prognosis

华琪, 陈琦, 游览. 142例抗结核药物性肝损伤患者临床特征分析^*[J]. 实用肝脏病杂志, 2021, 24(6): 843-846.

Hua Qi, Chen Qi, You Lan. Clinical feature of 142 patients with anti-tuberculosis agents-induced DILI[J]. Journal of Practical Hepatology, 2021, 24(6): 843-846.

参考文献

[1] Mao Q, Zhang K, Yan W, et al. Forecasting the incidence of tuberculosis in China using the seasonal auto-regressive integrated moving average (SARIMA) model. J Infect Public Health, 2018, 11: 707-712.
[2] Chen Y, Ye P, Ren C, et al. Pharmacoeconomics of three therapeutic schemes for anti-tuberculosis therapy induced liver injury in China. Open Med (Wars), 2018, 13: 53-63.
[3] Fang WC, Adler NR, Graudins LV, et al. Drug-induced liver injury is frequently associated with severe cutaneous adverse drug reactions: experience from two Australian tertiary hospitals. Intern Med J, 2018, 48(5):549-555.
[4] Dragovic S, Vermeulen NP, Gerets HH, et al. Evidence-based selection of training compounds for use in the mechanism-based integrated prediction of drug-induced liver injury in man. Arch Toxicol, 2016, 90(12):2979-3003.
[5] Chen SS, Yu KK, Huang C, et al. The characteristics and clinical outcome of drug-induced liver injury in a Chinese hospital: A retrospective cohort study. Medicine (Baltimore), 2016, 95(34):e4683.
[6] Li F, Lu S. Interpretation of expert recommendation on diagnosis and treatment of anti-tuberculosis drug-induced liver injury. Community Acquir Infect, 2015, 2: 113.
[7] Wu T, Bai H, Zhao Z, et al. A prospective study on associations between superoxide dismutase gene polymorphisms and antituberculosis drug-induced liver injury in a Chinese Han population. J Gene Med, 2019, 21(10):e3121.
[8] Wang R, Qi X, Yoshida EM, et al. Clinical characteristics and outcomes of traditional Chinese medicine-induced liver injury: a systematic review. Expert Rev Gastroenterol Hepatol, 2018, 12(4):425-434.
[9] Shen T, Liu Y, Shang J, et al. Incidence and etiology of drug-induced liver injury in mainland China. Gastroenterology, 2019, 156(8):2230-2241.
[10] Serper M, Wolf MS, Parikh NA, et al. Risk factors, clinical presentation, and outcomes in overdose with acetaminophen alone or with combination products: results from the acute liver failure study group. J Clin Gastroenterol, 2016, 50(1):85-91.
[11] 中华医学会肝病学分会药物性肝病学组. 药物性肝损伤诊治指南. 中华肝脏病杂志, 2015, 23(11):810-820.
[12] Yu YC, Mao YM, Chen CW, et al. CSH guidelines for the diagnosis and treatment of drug-induced liver injury. Hepatol Int, 2017, 11: 221-241.
[13] Gu J, Tang SJ, Tan SY, et al. An open-label, randomized and multi-center clinical trial to evaluate the efficacy of silibinin in preventing drug-induced liv-er injury. Int J Clin Exp Med, 2015, 8: 4320-4327.
[14] Zhang M, Wang S, Wilffert B, et al. The association between the NAT2 genetic polymorphisms and risk of DILI during anti-TB treatment: A systematic review and meta-analysis. Br J Clin Pharmacol, 2018, 84: 2747-2760.
[15] Chang TE, Huang YS, Chang CH, et al. The susceptibility of anti-tuberculosis drug-induced liver injury and chronic hepatitis C infection: A systematic review and meta-analysis. J Chin Med Assoc, 2018, 81: 111-118.
[16] Ichai P, Saliba F, Antoun F, et al. Acute liver failure due to antitubercular therapy: Strategy for antitubercular treatment before and after liver trans-plantation. Liver Transpl, 2010, 16: 1136-1146.
[17] Kumar R, Bhatia V, Khanal S, et al. Antituberculosis therapy-induced acute liver failure: Magnitude, profile, prognosis, and predictors of outcome. Hepatology, 2010, 51: 1665-1674.
[18] Ramappa V, Aithal GP. Hepatotoxicity related to anti-tuberculosis drugs: mechanisms and management. J Clin Exp Hepatol, 2013, 3: 37-49.
[19] Chang KC, Leung CC, Yew WW, et al. Hepatotoxicity of pyrazinamide: cohort and case-control analyses. Am J Respir Crit Care Med, 2008, 177: 1391-1396.
[20] Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: The diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol, 2014, 109: 950-967.

142例抗结核药物性肝损伤患者临床特征分析^*

Clinical feature of 142 patients with anti-tuberculosis agents-induced DILI

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	杜云飞, 刘景瑞, 叶飞翔. N-乙酰半胱氨酸联合双环醇治疗抗结核药物所致的药物性肝损伤患者疗效研究^*[J]. 实用肝脏病杂志, 2021, 24(6): 847-850.
[2]	刘积庆, 于国英, 杨生森, 黄群, 保成兰. 多种预后评分系统预测慢加急性肝衰竭并发真菌感染患者短期预后价值分析^*[J]. 实用肝脏病杂志, 2021, 24(6): 851-854.
[3]	管海燕, 杨文斌. 药物性肝损伤患者临床特点及预后分析^*[J]. 实用肝脏病杂志, 2021, 24(5): 713-716.
[4]	黄霜湘, 姚朝光, 蓝婧, 欧琴, 覃冬林, 陈丽芬, 黄洁婕. 慢加急性乙型肝炎肝衰竭患者血清自噬相关蛋白水平及其临床意义探讨^*[J]. 实用肝脏病杂志, 2021, 24(5): 721-724.
[5]	宋雪, 席子涵, 李婷, 周苗. 肝内胆管癌患者血清CXCL9和IFN-γ水平变化及其临床意义探讨[J]. 实用肝脏病杂志, 2021, 24(5): 741-744.
[6]	李变利, 徐丽红. 药物性肝损伤、药物诱导性自身免疫性肝炎和自身免疫性肝炎鉴别诊断研究进展^*[J]. 实用肝脏病杂志, 2021, 24(4): 460-463.
[7]	鲁小龙, 解春宝. IL-6基因多态性对HBV相关ACLF患者短期预后的影响[J]. 实用肝脏病杂志, 2021, 24(4): 516-519.
[8]	金苏素, 颜华东. 血清肾上腺髓质素前体诊断失代偿期肝硬化并发细菌感染及其预测短期预后的价值^*[J]. 实用肝脏病杂志, 2021, 24(4): 528-531.
[9]	张兵, 陈瑞红, 杨威, 徐刚. 肝细胞癌患者血清HSP90α和PIVKA-Ⅱ水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2021, 24(4): 548-551.
[10]	王婷婷, 辛洋, 王娜娜. 肝细胞癌癌组织CBX7和PERK表达及其对手术治疗后患者预后的影响^*[J]. 实用肝脏病杂志, 2021, 24(4): 552-555.
[11]	于哲, 罗婧, 杨永平. 外周血单个核细胞GPSM2水平可能是肝细胞癌预后判断的新型标志物^*[J]. 实用肝脏病杂志, 2021, 24(4): 556-560.
[12]	于涛, 李奎武, 姚琳, 吕武. 胆囊癌患者胆囊癌组织泛素结合酶E2T蛋白表达及其临床意义探讨^*[J]. 实用肝脏病杂志, 2021, 24(4): 593-596.
[13]	王梦雨, 杨蕊旭, 范建高. 重视代谢相关脂肪性肝病的特征与预后临床研究^*[J]. 实用肝脏病杂志, 2021, 24(3): 308-311.
[14]	陈晨, 王联发, 王艳, 唐郡, 张骏飞, 黄猛珣, 刘波. 112例新型冠状病毒肺炎患者肝肾功能和心肌酶学变化分析[J]. 实用肝脏病杂志, 2021, 24(3): 351-354.
[15]	黄春洋, 陈杰, 张小丹, 黄云丽, 韩莹, 李文娟, 边新渠, 廖慧钰, 单晶, 刘燕敏. 临床诊断的肝细胞型急性药物性肝损伤患者血清ALT/ALP比值变化特点与组织病理学特征分析[J]. 实用肝脏病杂志, 2021, 24(3): 379-382.